Tyr228
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr228  -  SPRED2 (human)

Site Information
EKIWMTGyEDyRHAP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 471403

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 1 ) , mutation of modification site ( 2 ) , western blotting ( 2 )
Disease tissue studied:
neuroblastoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
EGFR (human) ( 2 )
Treatments:
EGF ( 2 ) , vanadate ( 2 )

Downstream Regulation
Effects of modification on SPRED2:
protein degradation ( 2 )

References 

1

Guo A (2010) CST Curation Set: 10549; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

2

Lock P, et al. (2006) Spred-2 steady-state levels are regulated by phosphorylation and Cbl-mediated ubiquitination. Biochem Biophys Res Commun 351, 1018-23
17094949   Curated Info